Both worlds over time
Technical and news signals of the last 90 days on one timeline.
VST fundamental outlook?
From news analysis — different time windows than the trading horizons above
- VST trades at ~14x forward earnings, 33-47% below consensus, with a median analyst price target of $219 implying ~45% upside.
- CEO James Burke's $903K insider purchase at $135.49 signals confidence; analysts maintain Strong Buy with 43.6% upside.
- AI-driven power demand narrative strengthened by 20-year PPAs with Amazon, Meta, and New Era Energy, plus a JV with NVIDIA, KKR, and Kuwait Investment Authority.
- Execution risks: Q2 net income slipped 6.7% to $305M, FCF declined, and Moss Landing disruptions create near-term overhang.
- Legislative tailwind: House-passed Ratepayer Protection Act supports nuclear/SMR stocks, benefiting Vistra's 6.5 GW nuclear fleet.
Over the past month, VST has been driven by a mix of AI-driven power demand narratives and specific corporate developments. The most recent signal (Oct 8) is a bullish patent allowance for portfolio company Insu Therapeutics, boosting sentiment. Earlier, a series of mid-term signals highlighted Vistra's strategic positioning: a 20-year PPA with New Era Energy (5% non-voting interest), a JV with NVIDIA/KKR/KIA, and new 20-year deals with Amazon and Meta. The stock trades at ~14x forward earnings, 33-47% below consensus, with a median analyst price target of $219 (44.9% upside). CEO insider buying at $135.49 adds confidence. However, neutral signals flag execution risks: Q2 net income slipped 6.7% to $305M, FCF declined, and Moss Landing disruptions. The House-passed Ratepayer Protection Act and Anthropic IPO are structural tailwinds. Overall, the narrative is strongly bullish on AI-driven power demand, but near-term execution and valuation concerns temper conviction.
23 days ago · Based on 11 signals
Economic data for VST
Full calendarRecently released
- October 29, 2026USDPCE Price Index y/y●●●Forecast 3.3%Previous 3.4%
- October 29, 2026USDInitial Jobless Claims●●●Forecast 199KPrevious 194K
- October 29, 2026USDPCE Price Index m/m●●●Forecast 0.4%Previous 0.3%
- October 29, 2026USDCore PCE Price Index y/y●●●Forecast 3.1%Previous 3.0%
- October 29, 2026USDCore PCE Price Index m/m●●●Forecast 0.2%Previous 0.2%
- October 29, 2026USDGDP Sales q/q●●●Forecast 2.7%Previous 2.8%
- October 29, 2026USDGDP q/q●●●Forecast 1.4%Previous 2.2%
Coming up
- TomorrowUSDISM Manufacturing Prices Paid●●●Forecast 80.7Previous 77.9in 1 day
- TomorrowUSDISM Manufacturing PMI●●●Forecast 54.7Previous 54.5in 1 day
- November 3, 2026USDJOLTS Job Openings●●●Forecast 6.779MPrevious 7.079Min 2 days
- November 4, 2026USDADP Nonfarm Employment Change●●●Forecast 64KPrevious 90Kin 3 days
- November 4, 2026USDISM Non-Manufacturing Prices Paid●●●Forecast 69.5Previous 74.0in 3 days
- November 4, 2026USDISM Non-Manufacturing PMI●●●Forecast 55.2Previous 54.9in 3 days
- November 4, 2026USDEIA Crude Oil Stocks Change●●●in 3 days
- November 5, 2026USDInitial Jobless Claims●●●in 4 days
All times UTC. Assessed against the consensus forecast, otherwise against the previous value.
What is being reported about VST
📝 Overview Generated automatically?
VST has been the subject of 11 signals across 11 articles in the last 365 days. Sentiment skews Bullish (64%).
Breakdown: 7 bullish, 0 bearish, 4 neutral. AI confidence averages 59% across all signals.
Most-cited catalysts: U.S. patent allowance for Insu Therapeutics' platform (1×), Exclusive worldwide UBC license (1×). Most-cited risk factors: Dependence on the commercial success of portfolio companies (1×), Regulatory hurdles in the pharmaceutical distribution space (1×).
Related assets
Same category or comparable signal picture — each card opens the full cockpit.